Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to -$7.1 million.

  • Regenxbio's Cash from Financing Activities rose 3476.1% to -$7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $118.6 million, marking a year-over-year increase of 3408.73%. This contributed to the annual value of $92.7 million for FY2024, which is 36506.61% up from last year.
  • As of Q3 2025, Regenxbio's Cash from Financing Activities stood at -$7.1 million, which was up 3476.1% from $139.2 million recorded in Q2 2025.
  • In the past 5 years, Regenxbio's Cash from Financing Activities ranged from a high of $211.3 million in Q1 2021 and a low of -$12.0 million during Q4 2023
  • Moreover, its 5-year median value for Cash from Financing Activities was -$7.1 million (2025), whereas its average is $18.4 million.
  • Examining YoY changes over the last 5 years, Regenxbio's Cash from Financing Activities showed a top increase of 755251.72% in 2021 and a maximum decrease of 43627.4% in 2021.
  • Regenxbio's Cash from Financing Activities (Quarter) stood at -$7.6 million in 2021, then dropped by 17.12% to -$8.9 million in 2022, then plummeted by 34.1% to -$12.0 million in 2023, then surged by 35.3% to -$7.7 million in 2024, then grew by 8.49% to -$7.1 million in 2025.
  • Its Cash from Financing Activities stands at -$7.1 million for Q3 2025, versus $139.2 million for Q2 2025 and -$5.8 million for Q1 2025.